|
Pfizer CEO Stands by His Plan,
Frustrating Investors
April 17, 2008—Pfizer
plans to reverse falling profit by depending on sales boosts of
newer drugs instead of making a large acquisition to add
products. Kindler said that he sees no large deals for Pfizer,
at this time, where the risk and cost would outweigh the
benefit. He plans to increase sales of products marketed outside
the U.S. and speed new medicines to market. He also said the
company will continue to cut costs to counter declining revenue
and stay profitable.
Bloomberg
|
